Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (March 2023)
48 slides from Adocia Sa's investor presentation, March 2023
Slide 1: Corporate Presentation March 2023
Corporate Presentation March 2023
Slide 2: Disclaimer
Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain well as the trends in the sector in which the Group been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the operates, may differ materially from those
Slide 3: Highly experienced management team
Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, President & CEO R&D Director Chief Financial Officer Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy • Co-founde
Slide 4: Executive Summary
Executive Summary Our mission: development of innovative formulations of approved 1 peptides and novel cell therapy approaches for diabetes and obesity Our projects are based on 4 proprietary technologies: BioChaperone®, 2 AdOral®, AdoShell® and AdoGel®, with 4 products in clinical trials Business m
Slide 5: Business Strategy: a solid partnership and promising projects
Business Strategy: a solid partnership and promising projects Partnered Products: Supporting THDB, Partnership with Tonghua Dongbao Milestones (80M$) + royalties to be received BC Lispro and BC Combo Proprietary Products to M1Pram AdoShell Islets be licensed: BC Lispro UE/US Market potential: multi-
Slide 6: A diversified specialty products pipeline
A diversified specialty products pipeline Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones Partner Phase 3 in China ongoing Diabetes BC Lispro Ultra-Rapid Insulin Phase 3 in USA and Europe U100 / U200 ready to start* Asia & other territories Insulins Combination Phases 1 ongoing BC Com
Slide 7: Partnering models based on proprietary technology platforms with strong IP strategy
Both Adocia’s partnering models are based on proprietary technology platforms with strong IP strategy BioChaperone® AdOral® AdoShell® AdoGel® • Pharmaceutical excipient • Pharmaceutical excipient • Hydrogel scaffold • Biomaterial • Forms a complex with • Enhances proteins/peptides • Encapsulation of
Slide 8: Diabetes and Obesity: worldwide chronic pandemics
Diabetes and Obesity: worldwide chronic pandemics 537 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes and 85% of type 24 are overweight or obese, making DIABESITY a new pandemic • Several hormones are involved in both
Slide 9: Proprietary specialty products based on approved drugs
Proprietary specialty products based on approved drugs 9 9
Slide 10: BioChaperone Lispro
BioChaperone® Lispro Best-in-class Ultra Rapid Acting Insulin for a tighter glycemic control 10 10
Slide 11: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class
BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators AUC0-2h: -61%* • Good tolerance for optimized daily use • Range of strengths (U100
Slide 12: BC Lispro in phase 3 program in China with Tonghua Dongbao
BC Lispro in phase 3 program in China with Tonghua Dongbao Market • Prandial insulin WW market: $8bn1 • Insulin and analogs in China’s public medical institutions (2020) : c. $4 billion Partnership with Tonghua Dongbao (2018) • Licensed for development & commercialization for China and other Asian t
Slide 13: BC Combo, glargine-lispro premix
BC Combo, glargine-lispro premix The best insulin premix 13 13
Slide 14: BC Combo, a unique combination of glargine and lispro
BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL lispro) Less hyperglycemia Simple Affordable Less hypoglycemia Limited number of injections
Slide 15: BC Combo is licensed to Tonghua Dongbao in China
BC Combo is licensed to Tonghua Dongbao in China Premix market Tonghua Dongbao deal $2.7bn1 Western Markets: T2D patients • $40m upfront $2.3bn1 • $50m upcoming development Emerging Markets: milestones T1D & T2D • Double-digit royalties on sales ~65% patients Market share in India and China (volume)
Slide 16: AdoShell islets to cure Type 1 Diabetes
AdoShell® islets to cure Type 1 Diabetes Immuno-protective scaffold for pancreatic islet transplant 16 16
Slide 17: Adocia's vision of metabolic diseases treatment
Adocia’s vision of metabolic diseases treatment: from hormonal to cell therapies Immuno-protective scaffold for Islets of Langerhans Oral Delivery of hormones Multi-hormonal formulations Improved proteins/peptides formulations Adocia is taking on high challenges, that require innovative mindset and
Slide 18: Islets transplantation has many limitations
Islets transplantation has changed lives of patients living with unstable diabetes, but it still has many limitations • Among 40 million people living with T1D worldwide, 75 000 have a form particularly unstable (sometimes called “brittle”) • Life expectancy 27- to 45-year-old • Approx. 1,000 cases
Slide 19: AdoShell, an immuno-protective scaffold for islets transplantation
Adocia has developed AdoShell®, an immuno-protective scaffold for islets of Langerhans transplantation for brittle diabetes Hydrogel Reagents Immuno-isolation AdoShell Islets Ab, T cells Large entities > 10 nm + Insulin secreting cells • 1st generation: islets of Langerhans from deceased donors Free
Slide 20: AdoShell: ultra-thin, immuno-protective hydrogel film
AdoShell® : An ultra-thin, immuno-protective hydrogel film for cells encapsulation High water content for cell compatibility ✓ Immuno-isolating gel ✓ Ultra-thin aseptic film ✓ High cell density for miniaturization ✓ Biocompatible ✓ Mechanically resistant ✓ Implantable by mini-invasive surgery ✓ Retr
Slide 21: POC in diabetic rat: glycemia controlled during a 132-day study
POC in diabetic rat: glycemia controlled during a 132-day study without immunosuppressor 1. Transplantation of AdoShell containing allogenic islets in diabetic rat peritoneum at day 0 2. Explantation of the implant at day 132. Sacrifice of control group at day 35 Glycemia Body Weight Insulin Transpl
Slide 22: AdoShell provides a platform opening to many cell therapy markets
AdoShell provides a platform, opening to many cell therapy markets Cell therapy would benefit from AdoShell ✓ Safe and efficient cell engraftment ✓ Safely removable and replaceable transplantation ✓ Containment of proliferative cells ✓ No need of immunosuppressors, no need of gene-editing strategy f
Slide 23: Insulin & Amylin analogs combinations: M1Pram and BC LisPram
Insulin & Amylin analogs combinations: M1Pram and BC LisPram Breakthrough treatments to address the unmet medical need of overweight patients living with diabetes 23 23
Slide 24: M1Pram, a bi-hormonal therapy for obesity and diabetes
M1Pram, a bi-hormonal therapy to treat people with obesity and diabetes Higher risk of co-morbidities Obesity DIABESITY Diabetes Amylin Analog Insulin Analog Pramlintide M1 To control weight To control glycemia Insulin causes weight gain Obesity is a main concern for patients under intensive insulin
Slide 25: Amylin is missing in people with insulin-dependent diabetes
Amylin is missing in people with insulin-dependent diabetes, and it contributes to diabetes dysregulations Meal Insulin Normal pattern Amylin exerts important physiological effects on Level of secretion metabolism and weight control (relative scale) Amylin Glucagon 1. Activates amylin receptors in d
Slide 26: One formulation for pen - one for pump
One formulation for pen - one for pump Type Preclinic Phase 1 Phase 2 Phase 3 Regular insulin Clinical + Pramlintide M1Pram POC in Pen (MDI) Rapid insulin Phase 1 T1D pump study: + Pramlintide • Clinical part completed BC LisPram • Q1 2023 : results in Pump communication MDI: Multiple Daily Injectio
Slide 27: M1Pram reduces body weight with high efficacy in T1D with obesity
M1Pram reduces body weight with high efficacy in T1D with obesity CT041 : Phase 2 study – M1Pram vs. lispro (Humalog®) - type 1 diabetes - 16 weeks ambulatory Body Weight Change from Baseline to Week 16 All patients BMI ≥ 25 kg/m² BMI ≥ 30 kg/m2 (p value = 0.001) (post hoc, p value = 0.03) Mean +/-
Slide 28: Maintained glycemic control, with 21% reduction in prandial insulin dose
Maintained glycemic control, with 21% reduction in prandial insulin dose Change from baseline* Mean (SD) P-value M1Pram Lispro HbA1c (%) 0.14 (0.51) 0.10 (0.51) 0.81 (NS) Time-In-Range 70-180 mg/dL (%) -3.17 (8.76) -1.54 (8.87) 0.29 (NS) Prandial insulin dose (U/d) -5.97(6.18) -0.61(7.08) <0.001 Whi
Slide 29: Medical value of M1Pram insulin pramlintide combination is confirmed
Medical value of M1Pram insulin pramlintide combination is confirmed ✓ Significant weight loss is demonstrated • Strong effect in patients with obesity and T1D ✓ Satiety effect is induced ✓ Sparing effect on prandial insulin dose ✓ Product is well tolerated and safe ✓ Glycemic control is maintained
Slide 30: M1Pram in pen generates high expectations from KOLs
M1Pram in pen generates high expectations from KOLs “The phase 2 study of M1Pram shows that a single injection with “The glycemic results with M1Pram (P1b) are each meal is as easy to use and as efficient as Humalog for quite promising as is the observed weight loss, glycemic control without increas
Slide 31: BC LisPram: the optimal combination for pumps
BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill Adocia developed a fixed-dose combination of Lispro and University, Canada, by Dr. Ahmad Haidar Pram to be delivered in one single pump Lispro in one pump vs. Lispro and Pramlintide administered simultaneo
Slide 32: Obesity
Obesity Personalized multi-hormonal obesity treatment: a new paradigm “At Adocia, we believe that long lasting victory against obesity will come from the patients – so let’s give them the tools they need” 32 32
Slide 33: Obesity, new therapies for a worldwide chronic pandemic
Obesity, new therapies for a worldwide chronic pandemic • 650 million adults are obese Recent therapeutic breakthroughs 1. Long acting GLP-1, Semaglutide • 1.9 billion are overweight (Wegovy®, Novo Nordisk) 2. Long acting dual agonist GLP-1 GIP, • Of the 42.4% Americans who are obese, Tirzepatide (M
Slide 34: Patient-centric treatments with short-acting hormones delivered by a pump
Adocia is developing patient-centric treatments with short-acting hormones delivered by a pump DRUG-DEVICE COMBINATION « STOP-AND-GO » CONCEPT n days infusion n days infusion 1 day off Concentration The patient wears a patch-pump 4x to deliver combination of short acting hormones Concentration Expec
Slide 35: Combinations of diabetes hormones to treat obesity
Combinations of “diabetes” hormones appear to be a revolutionary way to treat obesity Weight loss %* 0 Current marketed AMYLIN treatments 5 Diabetes GLP-1 Obesity Mono-hormonal 15 GLUCAGON 20 Multi-hormonal Time Adocia has selected a combination of Glucagon and Exenatide, two hormones with different
Slide 36: BioChaperone Glucagon Exenatide (BC GluExe)
BioChaperone® Glucagon Exenatide (BC GluExe) Proof-of-Concept established in obese mice 120 110 100 Saline (vehicle) BC Exenatide* Exenatide “standalone” showed a significant 90 -10% Exenatide -10% weight loss compared to vehicle BW (%) 80 70 -25% BC Glucagon Exenatide*** showed a significant -25% w
Slide 37: AdOral
AdOral® A promising technology for oral delivery of peptides 37 37
Slide 38: Only 5 peptide therapeutics approved for oral delivery in a growing market
Only 5 peptide therapeutics have been approved for oral delivery in a growing market dominated by injectable forms Global Peptide Therapeutics Market* ($) *mAb excluded from the analysis Cyclosporin 39 Billion 48 Billion 1.2 kDa Approved 1995 Voclosporin Octreotide 50 Desmopressin 1.2 kDa 1.0 kDa GL
Slide 39: AdOral: a promising technology for oral delivery of peptides
AdOral: a promising technology for oral delivery of peptides AdOral is a unique formulation based on a new type of permeation enhancer (PE) combined with peptide protection against degradation AdOral form is a tablet or capsule Technology patented by Adocia The technology has been validated with Sem
Slide 40: Semaglutide with AdOral shows improved bioavailability in animal
Semaglutide formulated with AdOral has shown significantly improved bioavailability in animal Median Semaglutide PK Profile (N=10) Bioavailability of semagludide Rybelsus® formulated with AdOral: AdOral - semaglutide 5-fold higher median than Rybelsus Adocia seeks to establish proof of concept with
Slide 41: AdoGel
AdoGel® Long-acting drug delivery platform 41 41
Slide 42: AdoGel, a biomaterial for ultra long delivery of therapeutic agents
AdoGel, a biomaterial for ultra long delivery of therapeutic agents Adocia is developing a soft tissue-like biomaterial for sustained release of small molecules/biologics • Pharmaceutic forms • Implantable & Removable device • Injectable (in-situ forming gel) Implantable device Injection and in-situ
Slide 43: Sustained release of Levonorgestrel over 180 days
First application : sustained release of Levonorgestrel (LNG) over 180 days after SC administration in animal model Mean (±SE) PK profile Cumulative absorption No initial burst Pseudo-zero order AdoGel Preclinical proof of concept is ongoing with LNG Additional showcase studies are also ongoing with
Slide 44: Financial & news flow
Financial & news flow ADOCIA a
Slide 45: News flow
News flow BC Lispro M1Pram AdoShell® Islets • First-in-human study expected in • In China (with partner THDB): Phase • Additional Phase 2 study, 2023 3 ongoing under partnering condition AdoGel® • In USA/EU: Phase 3 ready to be BC LisPram • Preclinical Proof of Concept launched upon partnership sign
Slide 46: Key financials & shareholder information
Key financials & shareholder information, as of February 28, 2023 Key financials features Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €85m raised since inception • 8.9m shares outstanding • $125m received from partnerships Free float • ADR program in
Slide 47: Summary
Summary • Adocia’s projects are based on 4 proprietary technologies: BioChaperone®, AdOral®, AdoShell®, AdoGel® • A well-advanced and diversified pipeline with products ready-to-license: • 4 products in ongoing clinical trials: o BC Lispro Phase 3 in China o BC Combo clinical trials for qualificatio
Slide 48: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 [email protected]